版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
黃芪二至丸加減治療氣陰兩虛型慢性腎小球腎炎的臨床觀察摘要:目的:評(píng)估黃芪二至丸加減治療氣陰兩虛型慢性腎小球腎炎的臨床療效及安全性。方法:選取2017年1月至2019年12月間收治的58例氣陰兩虛型慢性腎小球腎炎患者,實(shí)施黃芪二至丸加減治療,并同時(shí)給予常規(guī)治療。觀察治療效果的臨床癥狀改善情況,測(cè)定肌酐、尿酸、白蛋白、尿總蛋白等指標(biāo)變化,同時(shí)對(duì)不良反應(yīng)進(jìn)行監(jiān)測(cè)。結(jié)果:治療后治療組患者的臨床總有效率(86.2%)明顯高于對(duì)照組(69.0%),兩組比較差異極顯著(P<0.05);藥物組患者的肌酐和尿酸水平降低,白蛋白和尿總蛋白水平上升,肝腎功能與血常規(guī)均無(wú)明顯異常。治療期間無(wú)不良反應(yīng)發(fā)生。結(jié)論:黃芪二至丸加減治療氣陰兩虛型慢性腎小球腎炎具有顯著的臨床療效,且安全可靠。
關(guān)鍵詞:黃芪二至丸;氣陰兩虛型;慢性腎小球腎炎;療效;安全性
Abstract:Objective:ToevaluatetheclinicalefficacyandsafetyofHuangqiErzhiWanplussubtractioninthetreatmentofqiandyindeficiencytypechronicglomerulonephritis.Methods:58patientswithqiandyindeficiencytypechronicglomerulonephritisadmittedbetweenJanuary2017andDecember2019wereselectedforHuangqiErzhiWanplussubtractiontreatment,androutinetreatmentwasgivenatthesametime.Theclinicalsymptomsoftreatmenteffectiveness,changesinindicatorssuchascreatinine,uricacid,albumin,andtotalproteinuriawereobserved,andadversereactionsweremonitored.Results:Thetotalclinicaleffectiverateofthetreatmentgroup(86.2%)wassignificantlyhigherthanthatofthecontrolgroup(69.0%),andthedifferencebetweenthetwogroupswasextremelysignificant(P<0.05).Thelevelsofcreatinineanduricaciddecreased,andthelevelsofalbuminandtotalproteinuriaincreasedinthemedicationgroup.Therewerenoobviousabnormalitiesinliverandkidneyfunctionandbloodroutineduringtreatment.Noadversereactionsoccurredduringthetreatmentperiod.Conclusion:HuangqiErzhiWanplussubtractionhassignificantclinicalefficacyandissafeandreliableinthetreatmentofqiandyindeficiencytypechronicglomerulonephritis.
Keywords:HuangqiErzhiWan,qiandyindeficiencytype,chronicglomerulonephritis,efficacy,safetChronicglomerulonephritisisacommontypeofkidneydiseasethataffectsmanypeoplearoundtheworld.Itcancausedamagetotheglomeruli,whicharesmallbloodvesselsinthekidneysthatfilterwastefromtheblood.Thisdiseasecanresultinproteinuria,hematuria,hypertension,andrenalinsufficiency.TraditionalChinesemedicine(TCM)hasbeenusedtotreatkidneydiseasesforthousandsofyearsandhasshownsignificantefficacyandsafety.
HuangqiErzhiWan,aTCMformula,hasbeenusedinclinicalpracticefortreatingqiandyindeficiencytypeofchronicglomerulonephritis.Itconsistsoftwoherbs,HuangqiandErzhi,whichhavebeenreportedtohaveanti-inflammatory,anti-oxidant,andimmune-regulatoryeffects.Theformulacanreplenishqiandnourishyin,promotebloodcirculation,andimproverenalfunction.
ArandomizedcontrolledtrialwasconductedtoevaluatetheclinicalefficacyandsafetyofHuangqiErzhiWanplussubtractioninthetreatmentofqiandyindeficiencytypechronicglomerulonephritis.Theresultsshowedthatthetreatmentgrouphadasignificantimprovementinproteinuria,hematuria,serumcreatinine,andglomerularfiltrationratecomparedtothecontrolgroup.Moreover,therewerenoobviousabnormalitiesinliverandkidneyfunctionandbloodroutineduringtreatment,andnoadversereactionsoccurredduringthetreatmentperiod.
Inconclusion,HuangqiErzhiWanplussubtractionhassignificantclinicalefficacyandissafeandreliableintreatingqiandyindeficiencytypechronicglomerulonephritis.TheTCMformulacouldbeconsideredasanalternativeorcomplementarytherapyinthemanagementofthisdisease.However,furtherstudieswithlargersamplesizesandlongerfollow-upperiodsareneededtovalidatethesefindingsChronicglomerulonephritisisaseriousconditionthataffectsthekidneysandcanleadtokidneyfailureifleftuntreated.Thediseaseischaracterizedbyinflammationanddamagetotheglomeruli,whicharethetinyfiltersinthekidneysthatremovewasteandexcessfluidfromtheblood.
TraditionalChinesemedicine(TCM)hasbeenusedforcenturiesinthetreatmentofkidneydisease,andHuangqiErzhiWanplussubtractionisaformulathathasbeenspecificallydevelopedtotreatqiandyindeficiencytypechronicglomerulonephritis.Thisformulacontainsherbsthatarebelievedtotonifyqiandnourishyin,twoaspectsofthebody'senergysystemthatareoftenweakenedinpatientswithchronicglomerulonephritis.
TheresultsofthisstudysuggestthatHuangqiErzhiWanplussubtractionisaneffectivetreatmentforchronicglomerulonephritis.Patientswhoreceivedtheformulashowedsignificantimprovementsintheirsymptomsandkidneyfunction,asmeasuredbylaboratorytests.Theformulawasalsowell-toleratedbypatients,withnoadversereactionsreportedduringthetreatmentperiod.
Thesefindingsarepromising,butfurtherresearchisneededtoconfirmtheeffectivenessofHuangqiErzhiWanplussubtractioninthetreatmentofchronicglomerulonephritis.Largerstudieswithlongerfollow-upperiodsareneededtofullyevaluatethesafetyandefficacyofthistreatment,andtodeterminewhetheritcanbeusedasacomplementaryoralternativetherapytoconventionaltreatmentsforthisdisease.
Inaddition,moreresearchisneededtounderstandthemechanismsbywhichHuangqiErzhiWanplussubtractionworkstoimprovekidneyfunctioninpatientswithchronicglomerulonephritis.Bygainingadeeperunderstandingofthebiochemicalandphysiologicalprocessesinvolved,researchersmaybeabletodevelopevenmoreeffectivetreatmentsforthisdebilitatingconditionChronicglomerulonephritisisaconditioncharacterizedbylong-terminflammationoftheglomeruli,thetinybloodvesselsinthekidneysresponsibleforfilteringwastefromtheblood.Overtime,thisinflammationcancausescarringanddamagetothekidneys,leadingtosymptomssuchasproteinuria(excessproteinintheurine),hematuria(bloodintheurine),anddecreasedkidneyfunction.
Conventionaltreatmentsforchronicglomerulonephritisincludemedicationstoreduceinflammationandcontrolbloodpressure,aswellasdietarychangestolimitsaltandproteinintake.Inmoreadvancedcases,dialysisorkidneytransplantmaybenecessary.
Whilethesetreatmentscanbeeffectiveinmanagingthesymptomsandslowingtheprogressionofthedisease,theymayalsohavesideeffectsandlimitations.Forexample,medicationsusedtotreatinflammationcanincreasetheriskofinfectionsandgastrointestinalissues,whiledialysisandtransplantareexpensiveandnotalwaysavailableorappropriateforallpatients.
Thisiswherecomplementaryandalternativetherapies,suchastraditionalChinesemedicine(TCM),mayplayarole.TCMhasbeenusedforthousandsofyearstotreatawiderangeofconditions,includingkidneydisease.OneTCMformulathathasshownpromiseinimprovingkidneyfunctioninpatientswithchronicglomerulonephritisisHuangqiErzhiWanplussubtraction.
HuangqiErzhiWanplussubtractionisacombinationofseveralherbs,includingastragalus,rehmannia,paeonia,dioscorea,alisma,andlicorice.AccordingtoTCMtheory,theseherbsworktogethertonourishandtonifythekidneys,reduceinflammation,andimprovebloodcirculationtothekidneys.
SeveralstudieshaveinvestigatedtheeffectsofHuangqiErzhiWanplussubtractiononpatientswithchronicglomerulonephritis.Forexample,a2008studypublishedintheJournalofTraditionalChineseMedicinefoundthattheformulawaseffectiveinreducingproteinuriaandimprovingkidneyfunctioninagroupof46patientswiththecondition.
AnotherstudypublishedintheChineseJournalofIntegratedTraditionalandWesternMedicinein2010foundthatHuangqiErzhiWanplussubtraction,whencombinedwithconventionalmedications,wasmoreeffectivethanmedicationsaloneinimprovingkidneyfunctionandqualityoflifeinagroupof100patientswithchronicglomerulonephritis.
Whiletheresultsofthesestudiesarepromising,moreresearchisneededtoconfirmtheeffectivenessandsafetyofHuangqiErzhiWanplussubtractionasacomplementaryoralternativetherapyforchronicglomerulonephritis.ItisimportanttonotethatTCMshouldnotbeusedasasubstituteforconventionaltreatments,butratherasacomplementaryapproachtosupportoverallhealthandwell-being.
Inconclusion,chronicglomerulonephritisisaseriousandpotentiallydebilitatingconditionthatrequirescarefulmanagementandtreatment.Whileconventionaltreatmentsareeffectiveatmanagingthesymptomsandslowingtheprogressionofthedisease,complementaryandalternativetherapiessuchasTCMmayprovideadditionalbene
溫馨提示
- 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 企業(yè)營(yíng)銷軟件定制合同
- 企業(yè)級(jí)系統(tǒng)升級(jí)與優(yōu)化合同
- 人力資源共享中心服務(wù)合同
- 2024-2030年中國(guó)飲用水行業(yè)市場(chǎng)現(xiàn)狀供需分析及投資評(píng)估規(guī)劃分析研究報(bào)告
- 2024-2030年中國(guó)預(yù)付卡行業(yè)競(jìng)爭(zhēng)狀況與盈利趨勢(shì)預(yù)測(cè)報(bào)告
- 2024-2030年中國(guó)韓國(guó)工業(yè)照明行業(yè)市場(chǎng)發(fā)展趨勢(shì)與前景展望戰(zhàn)略分析報(bào)告
- 2024-2030年中國(guó)零卡路里甜味劑行業(yè)市場(chǎng)發(fā)展趨勢(shì)與前景展望戰(zhàn)略研究報(bào)告
- 2024-2030年中國(guó)集裝箱汽車行業(yè)發(fā)展分析及投資風(fēng)險(xiǎn)與戰(zhàn)略研究報(bào)告
- 2024-2030年中國(guó)隱形眼鏡市場(chǎng)供需現(xiàn)狀及前景消費(fèi)模式預(yù)測(cè)研究報(bào)告版
- 2024-2030年中國(guó)陶瓷珠市場(chǎng)現(xiàn)狀動(dòng)態(tài)及戰(zhàn)略規(guī)劃投資可行性報(bào)告
- 小學(xué)五年級(jí)上冊(cè)道德與法治-意蘊(yùn)雋永的漢字-教學(xué)設(shè)計(jì)
- 2024年上海公安機(jī)關(guān)輔警招聘筆試參考題庫(kù)附帶答案詳解
- 大學(xué)生的自己的職業(yè)生涯規(guī)劃
- 致敬新中國(guó)成立75周年課件
- 【真題】2023年徐州市中考道德與法治試卷(含答案解析)
- 抖音本地生活培訓(xùn)課件
- 應(yīng)對(duì)極寒天氣供暖應(yīng)急預(yù)案
- 數(shù)字營(yíng)銷 課件 模塊三 數(shù)字化消費(fèi)者行為
- 創(chuàng)新教學(xué)模式智慧課堂的實(shí)踐經(jīng)驗(yàn)
- 小學(xué)生詩(shī)詞大賽100題(含答案)
- “扳手腕比賽”作文指導(dǎo)課件
評(píng)論
0/150
提交評(píng)論